Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Daytrana Patch Side Effects Linked to Reports of Skin Problems, Discoloration: FDA June 25, 2015 Irvin Jackson Add Your Comments Amid reports of problems with Daytrana patch involving permanent loss of skin color, federal drug regulators have issued new warnings for users of the skin patch used to treat Attention Deficit Hyperactivity Disorder (ADHD). In a drug safety communication issued on Wednesday, the FDA indicated that side effects of Daytrana Patch may include chemical leukoderma, which occurs when the skin loses color due to repeated exposure to certain chemicals. The agency said it will require the patch to carry new label warnings about the potential long-term risks. Reviewing information submitted to the FDA Adverse Event Reporting System (FAERS), the agency found at least 51 cases of Daytrana patch chemical leukoderma reported from April 2006 to December 2014, and indicates that there are likely many more cases of which it is unaware. Some experts estimate that the agency only receives notice of about 1% to 10% of all actual adverse events experienced by prescription drug users. Learn More About Daytrana Lawsuits Side Effects of Daytrana Patch May Cause Permanent Skin Color Changes and Scarring. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Daytrana Lawsuits Side Effects of Daytrana Patch May Cause Permanent Skin Color Changes and Scarring. Learn More SEE IF YOU QUALIFY FOR COMPENSATION According to the warning, the condition is not physically harmful, but it disfigures the victim. Reports of color loss have involved patches of skin up to eight inches in diameter. The condition occurs with repeated patch use and in the reports the FDA reviewed it can appear from two months to four years of Daytrana patch use. “In most cases, the loss of skin color was limited to the areas around where the patch was rotated. However, a small number of patients also reported skin color changes on parts of the body where the patch was never applied,” the FDA warning indicates. “In all cases, the decreased skin color was permanent.” The FDA urged patients or their caregivers to monitor for signs of skin color changes, particularly where the patch is applied. The agency also urged patients not to stop using the patch without first discussing it with a healthcare professional. Daytrana Patch Problems Daytrana (methylphenidate transdermal system) is a once-daily medicated patch, which was initially approved by the FDA in 2006 for treatment of ADHD. However, the medication has been linked to a number of potential health concerns in recent years. In a January 2013 report by the Institute for Safe Medication Practices (ISMP), problems with Daytrana patch were reported in more than 1,000 cases involving young children in the second quarter of 2012 alone. According to the report, adverse events associated with Daytrana over the four calendar quarters ending in the second quarter of 2012, exceeded those associated with any other drug monitored by the group. During that time period, out of all of the ADHD medications on the market, Daytrana accounted for only 3% of sales, but 99% of the complaints received by the FDA, leading ISMP reviewers to suggest that the FDA should consider issuing a Daytrana recall. In most cases, parents complained that the adhesive patch did not come off correctly, which can lead to problems sticking the patch to a child and uneven absorption of the medication, methylphenidate. However, many of the complaints also suggested children were suffering potentially serious side effects of Daytrana. Complaints included children suffering erythema, irritation, rashes, pruritus, burns, erosions, swelling vesicles, urticaria, and involuntary muscle movements. At least one case resulted in severe injury and hospitalization. About half of the Daytrona problems identified were linked to drug administration problems, with many parents indicating that problems removing the adhesive backing led to the patch falling off or causing trouble with applying it to their child. There were also 89 cases of drug prescribing error. The cases of involuntary movements were of particular concern, as in clinical trials there was at least one case where the child’s involuntary movements never resolved. The involuntary movements, often referred to as tardive dyskinesia, are a common complaint among some stimulants, but the ISMP report notes that health experts at the FDA are concerned that Daytrana tardive dyskinesia symptoms seem to appear more often than with other ADHD drugs. The complaints are nothing new for Daytrana. The first distributor, Dublin, Ireland-based Shire, gave up on the product in 2010, after 10 Daytrana recalls were issued since it was first approved in the United States. The patch’s distribution was taken over directly by Noven Pharmaceuticals, which has issued two recalls since then, one in March 2011 and another in September 2011. The problems with the adhesive being stuck to the protective liner was frequently the cause of the recalls. Additionally, in December 2013, the FDA issued another warning regarding a number of ADHD drugs, including Daytrana, linking them to long-lasting, and potentially dangerous, erections, known as priapism. Tags: ADHD, ADHD Drug, Daytrana, Skin Reactions, Tardive Dyskinesia More Daytrana Lawsuit Stories ADHD Drug Use Increasing Among Young Women, Trend Carries Pregnancy Risks: CDC January 23, 2018 Daytrana, Concerta Side Effects May Increase Risk of Heart Defects With Pregnancy Use: Study December 21, 2017 ADHD Drug Side Effects May Cause Heart Rhythm Problems in Some Children: Study June 3, 2016 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025) 12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025) BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)
Daytrana, Concerta Side Effects May Increase Risk of Heart Defects With Pregnancy Use: Study December 21, 2017
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025)
BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)